Abstract
Large randomized controlled trials have shown significant decrease in incidence of invasive fungal infection in acute myeloid leukemia patients with Posaconazole prophylaxis. However, very less is known about value of Posaconazole prophylaxis in resource limited settings. This observational cohort study evaluated the incidence of fungal infection in patients with hematological malignancies undergoing induction chemotherapy with Posaconazole as antifungal prophylaxis and was compared with historical controls who received Fluconazole as fungal prophylaxis. The study was conducted from Oct 2013 to July 2015 in Department of Hematology of a tertiary care center. Fifty-three patients of acute myeloid leukemia on Posaconazole as fungal prophylaxis and 53 historical controls on Fluconazole as fungal prophylaxis were included for final analysis. Baseline characteristics were well matched between groups. Patients on Fluconazole were more likely to experience breakthrough IFDs (28.3 and 11.3%; p = 0.028) than in patients receiving Posaconazole prophylaxis. No significant difference was observed in overall, attributable mortality or in shift to first line antifungal. Both Posaconazole and Fluconazole were well tolerated with no major adverse effects requiring discontinuation of the drug. Minor side effects were seen in 39 and 47% patients in study and control group respectively. Vomiting and nausea were the commonest side effects seen in both study and control group (26 vs. 34% and 38 vs. 40% of patients, respectively). The results of our study in patients with acute myeloid leukemia provide evidence that Posaconazole prophylaxis significantly decreases the incidence of fungal infection and is well tolerated.
Similar content being viewed by others
References
Barreto JN, Beach CL, Wolf RC, Merten JA, Tosh PK, Wilson JW et al (2013) The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole. Am J Hematol 88(4):283–288
Ananda-Rajah MR, Grigg A, Downey MT, Bajel A, Spelman T, Cheng A et al (2012) Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica 97(3):459–463
Maertens JA, Frère P, Lass-Flörl C, Heinz W, Cornely OA (2007) Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer Suppl 5(2):43–48
Seshadri S, Baumann MA (2008) Reverse isolation for neutropenic patients. Commun Oncol 5:628–632
Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H et al (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326(13):845–851
Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR et al (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation–a prospective, randomized, double-blind study. J Infect Dis 171(6):1545–1552
Cornely OA, Ullmann AJ, Karthaus M (2003) Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 101(9):3365–3372
Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356(4):348–359
Minetto P, Guolo F, Mikulska M, Pastori G, Giannoni L, Furfaro E et al (2014) Posaconazole for primary antifungal prophylaxis in AML patients: a real life single center experience and a comparison with the historical cohort. Blood 124(21):5255
Kung H-C, Johnson MD, Drew RH, Saha-Chaudhuri P, Perfect JR (2014) Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology–oncology patients: a retrospective cohort study. Cancer Med 3(3):667–673
Girmenia C, Frustaci AM, Gentile G, Minotti C, Cartoni C, Capria S et al (2012) Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica 97(4):560–567
Nagappan V, Deresinski S (2007) Posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 45(12):1610–1617
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical Approval
Ethical clearance was taken from the Institutional ethics committee.
Informed Consent
Informed consent was taken from all the participants of this study.
Rights and permissions
About this article
Cite this article
Bansal, D., Seth, T., Kumar, R. et al. Efficacy of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Induction Chemotherapy: An Observational Study in Resource Limited Settings. Indian J Hematol Blood Transfus 34, 460–465 (2018). https://doi.org/10.1007/s12288-018-0916-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-018-0916-2